About

Pyovita is a Danish biotechnology company developing new treatments for colorectal cancer. Our approach targets the protective extracellular matrix surrounding tumors — a major barrier that can limit drug penetration, protect resistant cancer cells, and reduce treatment effectiveness.

We are advancing two complementary product candidates: a standalone therapeutic for use with existing cancer treatments and an engineered bacterial therapy that produces the therapeutic locally and helps remodel the tumor microenvironment.

Our story

Pyovita was founded in 2024 as a spin-out from the Technical University of Denmark. The company builds on years of research in molecular microbiology, anticancer therapeutics, microbial engineering and the tumor microenvironment.

Our ambition is to translate this scientific foundation into treatments that make colorectal tumors more accessible and responsive to therapy.

Our team

Dr. Mariia Suvorova | Founder and CEO

Mariia is a molecular microbiologist, biotech entrepreneur, and anticancer drug developer with more than 20 years of industry experience. She previously founded and scaled biotechnology companies to approximately 200 employees and completed a successful company exit. She later conducted EU-funded research at DTU, where the scientific foundation for Pyovita was developed.

Raul Castilla | Researcher

Raul works full-time on Pyovita’s experimental development. He holds an MSc in biosynthetic engineering and contributes expertise in molecular biology, bacterial engineering, strain construction, and laboratory assay development.

Our network

Pyovita works with scientific, clinical, and commercial advisors with expertise in colorectal cancer, microbiome research, bacterial engineering, gut physiology, drug development, intellectual property, and biotech commercialisation.

Together, we combine scientific discovery, hands-on product development, and company-building experience to advance a new therapeutic approach for colorectal cancer.

Contacts